Clinical Trial Update: Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs). [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting immunogenicity and safety data for GSK's HBV-MPL vaccine and Engerix-B in healthy adults aged 15-40; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• HBV-MPL vaccine (HBV-MPL vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED